Researchers Submit Patent Application, "Reverse Genetics-Based Compositions Of Recombinant Sars-Cov-2", for Approval (USPTO 20240100150).
In: Vaccine Weekly, 2024-04-19, S. 10364-10364
serialPeriodical
Zugriff:
A patent application has been submitted for the approval of "Reverse Genetics-Based Compositions Of Recombinant Sars-Cov-2." The inventors highlight the urgent need for effective prophylactics and therapeutics for SARS-CoV-2 and COVID-19. The patent application describes the development of recombinant BAC constructs containing the recombinant SARS-CoV-2 genome for screening antiviral agents and vaccine development. These compositions have been used to track viral infections, identify chemical agents or neutralizing antibodies, and generate vaccines. The patent application also includes information on the safety, protection, and immunogenicity of live attenuated vaccines against SARS-CoV-2. [Extracted from the article]
Copyright of Vaccine Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Reverse Genetics-Based Compositions Of Recombinant Sars-Cov-2", for Approval (USPTO 20240100150).
|
---|---|
Zeitschrift: | Vaccine Weekly, 2024-04-19, S. 10364-10364 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1074-2921 (print) |
Sonstiges: |
|